ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ダサブビル

Dasabuvir

HCID 56640146
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
1132935-63-7
標準SMILES
COc1c(-c2ccc3cc(NS(C)(=O)=O)ccc3c2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C
InChIKey
NBRBXGKOEOGLOI-UHFFFAOYSA-N
分子式
C26H27N3O5S
平均分子量
493.6 g/mol
単同位体質量
493.16714214

概要

Dasabuvir is a member of the class of pyrimidone, which is (as the monohydrate of its sodium salt) in combination with ombitasvir, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver. It has a role as an antiviral drug and a nonnucleoside hepatitis C virus polymerase inhibitor. It is a member of naphthalenes, a sulfonamide, an aromatic ether and a pyrimidone. It is functionally related to a uracil.

名称と識別子

優先名称
Dasabuvir
IUPAC
N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide
現地名
ダサブビル
英語名
ABT-333
分子式
C26H27N3O5S
分子量
493.57

名称と別名

Dasabuvir1132935-63-7ABT-333ABT333exvieraDE54EQW8T1N-(6-(3-tert-Butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamideABT 333CHEBI:85182DTXSID301025953N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamideMethanesulfonamide, N-(6-(5-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-3-(1,1-dimethylethyl)-2-methoxyphenyl)-2-naphthalenyl)-
名称をさらに表示
ダサブビルN-[6-[3-(1,2,3,4-テトラヒドロ-2,4-ジオキソピリミジン-1-イル)-5-tert-ブチル-6-メトキシフェニル]ナフタレン-2-イル]メタンスルホンアミドN-{6-[3-tert-ブチル-5-(2,4-ジオキソ-1,2,3,4-テトラヒドロピリミジン-1-イル)-2-メトキシフェニル]ナフタレン-2-イル}メタンスルホンアミドCS-2000ABT-333/DasabuvirDasabuvir (ABT-333)Dasabuvir-13C 15N2 D3Dasabuvir, 10 mM in DMSON-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]-2-naphthyl}methanesulfonamideN-{6-[5-(2,4-Dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-2-methoxy-3-(2-methyl-2-propanyl)phenyl]-2-naphthyl}methanesulfonamide
N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamidedasabuvirumN-(6-(3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamideRefChem:585200J05AP09DTXCID901510205805-439-9N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide

物性

構造計算による物性

XLogP
4.3
極性表面積
113 Ų
水素結合供与体数
2
水素結合受容体数
6
回転可能結合数
6
重原子数
35
形式電荷
0
複雑度
938

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
Human DrugsBreast Feeding; Lactation; Milk, Human; Antiviral Agents

物理化学的性質

融点
192 oC · >192oC (dec.)
比重(密度)
1.317 · 1.317±0.06 g/cm3(Predicted)
貯蔵温度
-20 °C · Hygroscopic, -20°C Freezer, Under inert atmosphere
溶解性
クロロホルム(微熱)、DMSO(微熱)、メタノール(微熱)
外見
個体
酸解離定数(Pka)
8.52 · 8.52±0.30(Predicted)
色
ペールブラウンからライトブラウン
InChI
InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31)
InChIKey
NBRBXGKOEOGLOI-UHFFFAOYSA-N
SMILES
CS(NC1=CC=C2C(=C1)C=CC(C1=CC(N3C(=O)NC(=O)C=C3)=CC(C(C)(C)C)=C1OC)=C2)(=O)=O

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 3 件

H413 (100%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard]

P273, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.

危険有害性情報

Regulatory InformationREACH registered substance: N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide (EC: 805-439-9)
Hazard Classes and CategoriesAquatic Chronic 4 (100%)

毒性情報

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
WGK 3
Hazard Classifications
Aquatic Chronic 4
ストレージクラス
11 - Combustible Solids

化学と産業

薬理情報

ATC Code · 2 件

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

Protein BindingDasabuvir is greater than 99.5% bound to human plasma proteins.
PharmacodynamicsDasabuvir is classified as a direct-acting antiviral (DAA) and prevents viral replication in HCV genotype 1.
Mechanism of Action · 1 件

Dasabuvir is a non-nucleoside inhibitor of the HCV RNA-dependent RNA polymerase encoded by the NS5B gene, which is essential for replication of the viral genome. Based on drug resistance mapping studies of HCV genotypes 1a and 1b, dasabuvir targets the palm domain of the NS5B polymerase, and is therefore referred to as a non-nucleoside NS5B-palm polymerase inhibitor. The EC50 values of dasabuvir against genotype 1a-H77 and 1b-Con1 strains in HCV replicon cell culture assays were 7.7 nM and 1.8 nM, respectively. By binding to NS5b outside of the active site of the enzyme, dasabuvir induces a conformational change thereby preventing further elongation of the nascent viral genome. A limitation of binding outside of the active site is that these binding sites are poorly preserved across the viral genotypes. This results in a limited potential for cross-genotypic activity and increased potential for development of resistance. Dasabuvir is therefore limited to treating genotypes 1a and 1b, and must be used in combination with other antiviral products.

Biological Half-LifeThe half-life of elimination of dasabuvir is 5.5 to 6 hours.
Metabolism/MetabolitesDasabuvir is predominantly metabolized by CYP2C8, and to a lesser extent by CYP3A.
FDA Pharmacological Classification · 6 件

DE54EQW8T1

DASABUVIR

Established Pharmacologic Class [EPC] - Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor

Mechanisms of Action [MoA] - RNA Replicase Inhibitors

Mechanisms of Action [MoA] - UGT1A1 Inhibitors

関連反応

38 件
反応記録を作成
HRID 58403 の反応式
HRID 58403生成物として
HRID 58404 の反応式
HRID 58404生成物として
HRID 58405 の反応式
HRID 58405生成物として
HRID 58406 の反応式
HRID 58406生成物として
HRID 58407 の反応式
HRID 58407生成物として
HRID 58408 の反応式
HRID 58408生成物として
HRID 58409 の反応式
HRID 58409生成物として
HRID 58410 の反応式
HRID 58410生成物として
前へ1 / 5 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
1132935-63-7
PubChem CID
56640146
DTXSID
DTXSID301025953
ChEMBL
CHEMBL3137312
ChEBI
CHEBI:85182
UNII
DE54EQW8T1
EC Number
805-439-9
Nikkaji
J3.299.348F

Mechanisms of Action [MoA] - Breast Cancer Resistance Protein Inhibitors

Absorption, Distribution and Excretion · 4 件

Dasabuvir reaches peak plasma concentration 4 hours after administration. The absolute bioavailability of Dasabuvir is 70%.

Dasabuvir is mainly excreted in the feces (94.4%) with very little excreted in the urine (2%). 26.2% and 0.03% of the drug excreted in the feces and urine respectively was present as the parent compound suggesting metabolism as the major elimination pathway.

Dasabuvir has a volume of distribution at steady state of 149 liters.

Clearance of Dasabuvir has not been determined.

応用分野

使用Dasabuvir is an antiviral drug used in the treatment of chronic hepatitis C virus (HCV) infection.

上流・下流製品情報

上流原料

1-(3-tert-Butyl-5-iodo-4-Methoxyphenyl)pyriMidin-2,4(1H,3H)-dioneN-(6-(4,4,5,5-テトラメチル-1,3,2-ジオキサボロラン-2-イル)ナフタレン-2-イル)メタンスルホンアミド炭酸ナトリウムテトラキス(トリフェニルホスフィン)パラジウム(0)1,4-ジオキサン水和物
補足説明 · 1 件

定義ChEBI: A member of the class of pyrimidone, which is (as the monohydrate of its sodium salt) in combination with ombitasvir, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as c rrhosis of the liver.